Cardiff Oncology Inc
5.83 %
55.41 %
Yet to be announced
Company Overview
Cardiff Oncology is a clinical-stage biotechnology company focused on developing treatments for cancer patients. The company's primary focus is on developing onvansertib, a selective Polo-like Kinase 1 (PLK1) inhibitor, for various cancer indications, particularly targeting KRAS-mutated metastatic colorectal cancer, pancreatic cancer, and other solid tumors.
Revenue Sources
PassCardiff Oncology is a clinical-stage biotechnology company focused on developing cancer treatments. Their revenue comes primarily from licensing agreements and research collaborations related to their cancer drug development programs. There is no evidence of revenue from haram sources in their business model.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $109,000 | $14.49m | - | - | 0.00% | 0.00% |
| Dec. 31, 2024 | $150,000 | $12.72m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $165,000 | $12.77m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $163,000 | $12.71m | - | - | 0.00% | 0.00% |
The company is still in its pre-revenue R&D phase, focusing on developing cancer treatments. As a clinical-stage biotech company that hasn't yet commercialized its products, we skip the interest ratio checks as the company is not in its mature operational phase. The financial data shows zero interest income and expense over the past four quarters.
Operational Ethics
PassBased on review of the company's operations, clinical trial locations, and partnerships, there is no evidence of material ongoing associations with the state of Israel, Chinese Communist Party, or other entities involved in human rights violations.
Comments